List Of International Stocks
Discover investment opportunities in List Of International Stocks using our Smart AI Filter.
AI is processing your request...
AI is analyzing your request
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of International Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of International Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of International Stocks using our Smart AI Filter.
7 stocks found for "List Of International Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
---|---|---|---|---|---|---|
0.60 | ±19.1% | 13.0 | 4.10% | |||
0.45 | ±20.5% | 12.7 | 3.02% | |||
1.41 | ±45.9% | 11.0 | 1.84% | |||
0.64 | ±25.1% | 45.0 | 3.12% | |||
0.67 | ±23.5% | 9.8 | 18.34% | |||
0.71 | ±28.6% | 10.8 | 2.10% | |||
0.40 | ±24.1% | 25.7 | 3.66% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What growth potential does Alibaba (BABA) offer for investors?
A: Alibaba Group (BABA) has historically shown strong growth due to its dominance in China's e-commerce sector and expansion into cloud computing. However, investors should be aware of regulatory challenges and economic slowdowns that may affect performance.
Q: How has Teledoc Health (TDOC) performed during economic uncertainties?
A: Teledoc Health (TDOC) gained traction during the COVID-19 pandemic as demand for telehealth services increased. However, market volatility and competition can impact its growth trajectory moving forward.
Q: What makes Shopify (SHOP) appealing to growth-focused investors?
A: Shopify (SHOP) is attractive due to its role in enabling e-commerce for businesses globally. The company's innovative platform and growing merchant base drive revenue growth, though valuation concerns may pose risks.
Q: What specific risks does NIO (NIO) face in the electric vehicle sector?
A: NIO (NIO) encounters significant competition and regulatory challenges in China's electric vehicle market. Supply chain constraints and the need for substantial capital investment are additional considerations.
Q: How does Tata Consultancy Services (TCS) perform with the rise of digital transformation?
A: Tata Consultancy Services (TCS) benefits from the digital transformation trend, offering IT services globally. Its strong client relationships and diversified offerings bolster its competitive position in this fast-growing sector.
Q: What are Infosys's (INFY) competitive advantages in the IT services industry?
A: Infosys (INFY) leverages its extensive global presence, strong brand, and robust innovation practices, making it a leader in IT consulting. However, currency fluctuations and political landscapes can impact results.
SAP will invest more than 20 billion euros into its sovereign cloud capabilities in Europe over the next decade, the company announced Tuesday. The aim is to ensure customer data is stored within the EU to maintain compliance with regional data protection regulations like GDPR.
Read morePresident Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read more